home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Genetic News | search  

New Class Of Cancer Therapeutic

  July, 5 2006 7:12
your information resource in human molecular genetics
Scientists have created a new class of cancer drug that combines the targeting strength of one type of ribonucleic acid (RNA) therapy with the therapeutic potency of another. Bruce Sullenger and colleagues have created a hybrid drug molecule that not only precisely targets diseased prostate cancer cells but also reduces levels of proteins that normally protect cancer cells from self destructing. The cancer agent is shown to effectively kill prostate tumors in mice, in a paper to be published in the August issue of Nature Biotechnology.

Aptamers are short nucleic acids with highly specific shapes that enable them to bind tightly to specific protein targets. There is already one aptamer drug on the market for the treatment of the eye disease age-related macular degeneration. Small-interfering RNAs, which specifically block the formation of proteins, are also making headlines as they progress through to the clinic.

The team's new type of RNA therapy combines the exquisite targeting capacity of an aptamer, which binds to a protein expressed specifically on the surface of prostate cancer cells, with the ability of two siRNA molecules to destroy RNA messages within the cancer cells that promote their survival.

Until now, approaches for delivering siRNA therapies to patients have been hampered by poor efficiency, a lack of specificity and unwanted immune responses in patients. It is hoped that the incorporation of aptamers into other siRNA therapies may overcome some of these problems and provide an effective means of targeting and killing diseased cells, although this will clearly require further experiments and studies to establish long-term side-effects and benefits.

Author contact:

Bruce Sullenger (Duke Center for Translational Research, Durham, NC, USA)
E-mail: b.sullenger@cgct.duke.edu

Abstract available online.

(C) Nature Biotechnology press release.

Message posted by: Trevor M. D'Souza

print this article mail this article
Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2023 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.